ALX Oncology Announces Updated Data from ASPEN-01, the Ongoing Phase 1b Study of ALX148, Showing Robust, Durable Activity in Patients with Non-Hodgkin Lymphoma

Ads

You May Also Like

Shire plc : Director Declaration

Director Declaration July 24, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") ...

Medivir initiates phase IIa study of MIV-711 in knee osteoarthritis

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces the enrolment of the ...

Radius Health Reports Fourth Quarter and Full Year 2017 Financial and Operating Results and Provides Business Update

TYMLOS™ sales show accelerating market share growth, capturing approximately 32% of osteoporosis patients new ...